SCHEMBL3911569

SCHEMBL3911569

O=c1[nH]n(Cc2ccc(F)c(F)c2)c2ccc(NS(=O)(=O)c3cc(Cl)c(Cl)cc3Cl)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNA2 P20248 1/20 0.41
CCND1 P24385 1/20 0.41
CDK2 P24941 1/20 0.41
CDK7 P50613 1/20 0.41
CCNH P51946 1/20 0.41
CCNA1 P78396 1/20 0.41
CDK6 Q00534 1/20 0.41
ALDH1A1 P00352 2/20 0.38
PGR P06401 1/20 0.37
NR1I2 O75469 2/20 0.37
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3906967 0.94 PKM (0.40) CDK1CCNB1CCNA2CCND1CDK2
SCHEMBL3913835 0.93 LMNA (0.39) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL3906659 0.88 PTGES2 (0.47) ALDH1A1PGRNR1I2BRD4SLC22A12
SCHEMBL3904603 0.87 MAPT (0.46) ALDH1A1MAPTMEN1KMT2ACYP1A2
SCHEMBL3913785 0.86 PTGDR2 (0.48) ALDH1A1MAPTMEN1KMT2ACYP1A2
SCHEMBL3905782 0.86 GSPT1 (0.41) ALDH1A1NR1I2MAPTMEN1KMT2A
SCHEMBL5609434 0.84 CDK1 (0.39) CDK1CCNB1CCNA2CCND1CDK2
SCHEMBL3910618 0.84 SGK1 (0.41) ALDH1A1NR1I2BRD4PKMPTGDR2
SCHEMBL3917126 0.83 BRD4 (0.49) PGRMAPTBRD4PKMLMNA
SCHEMBL3909837 0.83 PFKFB3 (0.40) ALDH1A1NR1I2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 CDK1 1108/4885CCNB1 1645/4885CCNA2 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.